Organon [OGN] vs Amgen [AMGN] Detailed Stock Comparison
Organon
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Organon wins in 8 metrics, Amgen wins in 12 metrics, with 0 ties. Amgen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Organon | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 3.44 | 24.22 | Organon |
| Price-to-Book Ratio | 3.28 | 21.48 | Organon |
| Debt-to-Equity Ratio | 1,213.64 | 756.65 | Amgen |
| PEG Ratio | -0.13 | 0.27 | Organon |
| EV/EBITDA | 6.39 | 12.87 | Organon |
| Profit Margin (TTM) | 11.15% | 18.96% | Amgen |
| Operating Margin (TTM) | 21.08% | 32.73% | Amgen |
| EBITDA Margin (TTM) | 21.08% | 32.73% | Amgen |
| Return on Equity | 159.64% | 99.14% | Organon |
| Return on Assets (TTM) | 6.62% | 7.51% | Amgen |
| Free Cash Flow (TTM) | $588.00M | $10.39B | Amgen |
| Dividend Yield | 8.50% | 4.09% | Organon |
| 1-Year Return | -58.50% | -10.05% | Amgen |
| Price-to-Sales Ratio (TTM) | 0.38 | 4.57 | Organon |
| Enterprise Value | $10.71B | $207.78B | Amgen |
| EV/Revenue Ratio | 1.71 | 5.95 | Organon |
| Gross Profit Margin (TTM) | 54.83% | 67.20% | Amgen |
| Revenue per Share (TTM) | $24 | $65 | Amgen |
| Earnings per Share (Diluted) | $2.69 | $12.24 | Amgen |
| Beta (Stock Volatility) | 0.57 | 0.48 | Amgen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Organon vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Organon | 1.67% | -1.17% | -1.80% | 10.08% | -40.09% | -37.97% |
| Amgen | -0.74% | 1.88% | -0.04% | 9.00% | -2.39% | 14.07% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Organon | -58.50% | -68.74% | -72.09% | -72.09% | -72.09% | -72.09% |
| Amgen | -10.05% | 22.90% | 16.85% | 89.72% | 467.90% | 275.90% |
Performance & Financial Health Analysis: Organon vs Amgen
| Metric | OGN | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.41B | $159.61B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 4,624,446 | 2,389,100 |
| 90 Day Avg. Volume | 4,369,692 | 2,015,403 |
| Last Close | $9.44 | $293.58 |
| 52 Week Range | $8.01 - $23.10 | $253.30 - $339.17 |
| % from 52W High | -59.16% | -13.44% |
| All-Time High | $39.47 (Feb 28, 2022) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -76.08% | -15.36% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.09% |
| Quarterly Earnings Growth | -0.26% | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.19% |
| Operating Margin (TTM) | 0.21% | 0.33% |
| Return on Equity (TTM) | 1.60% | 0.99% |
| Debt to Equity (MRQ) | 1,213.64 | 756.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.82 | $13.80 |
| Cash per Share (MRQ) | $2.30 | $14.91 |
| Operating Cash Flow (TTM) | $826.00M | $12.01B |
| Levered Free Cash Flow (TTM) | $321.12M | $10.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | 8.50% | 4.09% |
| Last 12-Month Dividend | $0.84 | $11.64 |
Valuation & Enterprise Metrics Analysis: Organon vs Amgen
| Metric | OGN | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 3.44 | 24.22 |
| Forward P/E | 2.19 | 14.34 |
| PEG Ratio | -0.13 | 0.27 |
| Price to Sales (TTM) | 0.38 | 4.57 |
| Price to Book (MRQ) | 3.28 | 21.48 |
| Market Capitalization | ||
| Market Capitalization | $2.41B | $159.61B |
| Enterprise Value | $10.71B | $207.78B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.71 | 5.95 |
| Enterprise to EBITDA | 6.39 | 12.87 |
| Risk & Other Metrics | ||
| Beta | 0.57 | 0.48 |
| Book Value per Share (MRQ) | $2.82 | $13.80 |
Financial Statements Comparison: Organon vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OGN | AMGN |
|---|---|---|
| Revenue/Sales | $1.51B | $8.15B |
| Cost of Goods Sold | $672.00M | $2.97B |
| Gross Profit | $841.00M | $5.18B |
| Research & Development | $96.00M | $1.49B |
| Operating Income (EBIT) | $325.00M | $1.18B |
| EBITDA | $397.00M | $4.08B |
| Pre-Tax Income | $101.00M | $1.97B |
| Income Tax | $14.00M | $243.00M |
| Net Income (Profit) | $87.00M | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OGN | AMGN |
|---|---|---|
| Cash & Equivalents | $547.00M | $8.81B |
| Total Current Assets | $4.37B | $26.93B |
| Total Current Liabilities | $2.62B | $23.01B |
| Long-Term Debt | $8.94B | $54.01B |
| Total Shareholders Equity | $542.00M | $6.21B |
| Retained Earnings | $1.03B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OGN | AMGN |
|---|---|---|
| Operating Cash Flow | $13.00M | $1.71B |
| Capital Expenditures | N/A | $-411.00M |
| Free Cash Flow | $-22.00M | $980.00M |
| Debt Repayment | $-93.00M | $-2.50B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | OGN | AMGN |
|---|---|---|
| Shares Short | 15.01M | 12.52M |
| Short Ratio | 4.10 | 6.48 |
| Short % of Float | 0.08% | 0.02% |
| Average Daily Volume (10 Day) | 4,624,446 | 2,389,100 |
| Average Daily Volume (90 Day) | 4,369,692 | 2,015,403 |
| Shares Outstanding | 257.80M | 537.00M |
| Float Shares | 258.73M | 536.99M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.85% | 0.84% |
Dividend Analysis & Yield Comparison: Organon vs Amgen
| Metric | OGN | AMGN |
|---|---|---|
| Last 12-Month Dividend | $0.84 | $11.64 |
| Last 12-Month Dividend Yield | 8.50% | 4.09% |
| 3-Year Avg Annual Dividend | $1.03 | $9.51 |
| 3-Year Avg Dividend Yield | 1.46% | 0.80% |
| 3-Year Total Dividends | $3.08 | $28.54 |
| Ex-Dividend Date | Feb 24, 2025 | Aug 22, 2025 |